
The temporary exhibition (1 October 2016, to 20 January 2018) also included costumed interpreters
| Source Type | Legitimacy | Price Range | Risks |
|---|---|---|---|
| Online Black Market | Very Low | $50–$100 per pill | Fake medication, no quality control |
| Overseas Pharmacies | Moderate | $30–$80 per pill | Shipping delays, unregulated products |
| Counterfeit Vendors | High | $20–$70 per pill | Health hazards, legal issues |
portraying Colonel Lilly and others.
See "The Man Behind State's Most Successful Startup".
The company also stated that it would lower the price of Humalog from $275 a month to $66 and that it would offer insulin glargine at a 78% discount compared to rival company Sanofi. Despite this, the reduced costs will not apply to Eli Lilly's newer brands of insulin, and the company's pricing is still significantly higher than it was several decades prior. In August 2023, one of the first lawsuits was filed alleging that Novo Nordisk's Ozempic (semaglutide) and Eli Lilly's Mounjaro caused severe gastrointestinal side effects, including gastroparesis. [246] The lawsuit was brought on behalf of Jaclyn Bjorklund, a Louisiana woman represented by Morgan & Morgan, who alleged that she experienced persistent vomiting and other serious injuries after using both drugs and that the manufacturers failed adequately to warn patients and physicians about the associated risks. Judicial Panel on Multidistrict Litigation ordered that more than 50 lawsuits involving Ozempic and Mounjaro be centralised in the Eastern District of Pennsylvania.
Court filings showed that Morgan & Morgan had filed multiple cases and sought consolidation of the litigation. [247] Following the consolidation, the court appointed a plaintiffs' leadership committee to coordinate the litigation, which also included attorneys from the law firms Susen Law Group, Motley Rice, Levin Papantonio, cialis 5 mg tablet Pogust Goodhead, and Johnson Becker. In April 2025, Eli Lilly, represented by Kirkland & Ellis and Walsh Pizzi O'Reilly Falanga, filed a series of lawsuits in federal courts in New Jersey and California against several telehealth and compounding pharmacy companies, including Willow Health Services, Henry Meds, Mochi Health, Fella Health, and Empower Clinic Services, alleging unfair competition, false advertising, and deceptive business practices related to the sale of unapproved compounded tirzepatide products marketed for weight loss. [248] The company argued that the defendants sold compounded versions of tirzepatide without FDA approval or adequate testing and falsely claimed that their products were safe, effective, and superior to Lilly's FDA-approved drugs Mounjaro and Zepbound. [248] The defendants disputed the claims, characterising the lawsuits as an attempt by Eli Lilly to restrict competition and limit patient and provider choice in the weight-loss drug market.
In August 2025, U.S. District Judge Karen Marston issued the first substantive rulings in that multidistrict litigation, dismissing several claims while allowing the core allegations to proceed. [249] The court rejected portions of the plaintiffs' misrepresentation, medical monitoring, and design defect claims, but allowed claims alleging that Novo Nordisk and Eli Lilly failed to adequately warn patients about gastrointestinal risks on drug labels to move forward. The litigation at that stage encompassed more than 2,600 individual lawsuits involving Ozempic, Mounjaro, and related GLP-1 receptor agonist drugs. In August 2025, Texas sued Lilly for allegedly "bribing" providers to prescribe Mounjaro and Zepbound. Archived from the original on August 4, 2020.
| Medication | Active Ingredient | Usage Duration | Prescription Needed | Notes |
|---|---|---|---|---|
| Viagra | Sildenafil | 4–6 hours | Yes | Similar medication for ED |
| Levitra | Vardenafil | 4–5 hours | Yes | Alternative PDE5 inhibitor |
| Stendra (Spedra) | Avanafil | Up to 6 hours | Yes | Faster onset medication |
| Natural Supplements | Various herbal products | Varies | No | Efficacy and safety vary, consult doctor |
Archived from the original on January 12, 2017.
| Dosage | Average Price (per pill) | Source | Notes |
|---|---|---|---|
| 5 mg | $20–$30 | Licensed Canadian Pharmacies | Prescription required |
| 10 mg | $25–$35 | Canadian Online Pharmacies | Consult doctor before purchase |
| 20 mg | $30–$50 | Retail Pharmacies | Often available with insurance |
All In A Century: The First 100 Years of Eli Lilly and Company.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 40mg | 270 + 10 Pills | 382.19€ 363.99€ | |
| Cialis Generic | 60mg | 120 + 8 Pills | 240.18€ 228.74€ | |
| Cialis Professional | 20mg | 20 Pills | 78.33€ 74.60€ | |
| Cialis Generic | 20mg | 30 + 4 Pills | 68.05€ 64.81€ | |
| Cialis Original | 20mg | 120 + 8 Pills | 497.29€ 473.61€ | |
| Cialis Black | 80mg | 120 + 8 Pills | 264.77€ 252.16€ | |
| Cialis Generic | 2.5mg | 10 Pills | 28.51€ 27.15€ | |
| Cialis Original | 20mg | 14 + 2 Pills | 95.75€ 91.19€ | |
| Cialis Generic | 2.5mg | 20 Pills | 40.73€ 38.79€ | |
| Cialis Black | 80mg | 270 + 10 Pills | 502.88€ 478.93€ | |
| Cialis Generic | 60mg | 10 Pills | 41.22€ 39.26€ |
West Cornwall, CT: Eli Lilly and Company.
In March 2021, Eli Lilly and Company was accused of sex discrimination by a former lobbyist who claimed she was forced to work in a sexually hostile work environment. [235] The parties involved settled for an undisclosed amount in June 2021. In September 2021, Eli Lilly and Company was accused in a federal court lawsuit of discriminating against older applicants for sales positions based on their implementation of hiring quotas for millennials. In September 2013, Eli Lilly sued Canada for violating its obligations to foreign investors under the North American Free Trade Agreement by allowing its courts to invalidate patents for Atomoxetine (Strattera) and Olanzapine (Zyprexa). [238] Canadian courts found the seven-week long study of twenty-two patients for Atomoxetine (Strattera), too short and too narrow in scope to qualify for the patent.
The Olanzapine (Zyprexa) patent was invalidated because it had not achieved its promised utility. The company sought damages in the amount of $500 million for lost profits. They ultimately lost the case in 2017. In December 2005, Eli Lilly and Company pleaded guilty and paid $36 million in connection with the illegal promotion of Raloxifene (Evista), a medication typically used to prevent and treat osteoporosis in postmenopausal women. [240] Sales representatives were trained to promote Evista for breast cancer and cardiovascular disease, to prompt or bait questions from doctors, and to send them unsolicited letters promoting Evista for unapproved use.
The company also distributed a videotape in which a sales representative declared that "Evista truly is the best drug for the prevention of all these diseases." Some sales representatives had also been instructed to conceal the disclosure page which stated that the effectiveness of the drug in reducing breast cancer risks had not yet been established. In January 2019, lawmakers from the United States House of Representatives sent letters to Eli Lilly and other insulin manufacturers asking for explanations for rapidly raising insulin prices. The annual cost of insulin for people with type 1 diabetes in the US almost doubled from $2,900 to $5,700 over the period from 2012 to 2016. Renewed attention was brought to Eli Lilly's pricing of insulin in November 2022, after a verified Twitter account impersonating Eli Lilly posted on Twitter that insulin would now be free. [242][243][244] The following year, the company announced that it would be reducing the out-of-pocket price of insulin to $35 a month. Who's Who in America: A Biographical Dictionary of
Notable Living Men and Women of the United States.
^ a b c "Eli Lilly & Company" (PDF). Archived from the original (PDF) on July 29, 2016. "This month in 1876: Creation of Eli Lilly & Company". Archived (PDF) from the original on November 18, 2016. ^ The Indiana Historical Society recreated a replica of the first Lilly laboratory on Pearl Street for its exhibition, "You Are There: Eli Lilly at the Beginning," at the Eugene and Marilyn Glick Indiana History Center in Indianapolis. Indiana Legends: Famous Hoosiers From Johnny Appleseed to David Letterman.
Lilly allegedly offered illegal incentives to medical providers in Texas, including "free nurses" and reimbursement support services, while the costs of the drugs were covered by Medicaid. ^ a b c "Eli Lilly and Company 2025 Annual Report (Form 10-K)". ^ "Eli Lilly and Company 2023 Proxy Statement (Form DEF 14A)". "Novo investors seek clarity on Wegovy weight-loss drug shortages". "Eli Lilly opens $700 million research center on Fort Point spot where GE headquarters was once planned".
"Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles". "10 all-time greatest Eli Lilly drugs". Archived from the original on August 1, 2022. "Lizard-Derived Diabetes Drug Is Approved by the F.D.A.". Archived from the original on cialis plus priligy November 20, 2023. "Manufacturing Pharmaceuticals: Eli Lilly and Company, 1876–1948".
^ "Indiana State Historic Architectural and
Archaeological Research Database (SHAARD)" (Searchable database).
Internal documents provided to The New York Times revealed that Lilly had downplayed the risks of Zyprexa. According to the documents, 16 percent of people taking Zyprexa gained more than 66 pounds in their first year, a much larger figure than Eli Lilly had shared with doctors. In 2006, Lilly paid $700 million to settle around 8,000 of these lawsuits,[226] and in early 2007, Lilly settled around 18,000 suits for $500 million, which brought the total Lilly had paid to settle suits related to the drug to $1.2 billion. In March 2008, Lilly settled a suit with the state of Alaska,[228] and in October 2008, Lilly agreed to pay $62 million to 32 states and the District of Columbia to settle suits brought under state consumer protection laws. [229] In 2009, four sales representatives for Eli Lilly filed separate qui tam lawsuits against the company for illegally marketing Zyprexa for uses not approved by the Food and Drug Administration.
Eli Lilly pleaded guilty to a US federal criminal misdemeanor charge of illegally marketing Zyprexa, actively promoting the drug for off-label uses, particularly for the treatment of dementia in the elderly. [230] The $1.415 billion penalty included an $800 million civil settlement, a $515 million criminal fine, and forfeit assets of $100 million. [124] The US Justice Department said the criminal fine of $515 million was the largest ever in a healthcare case and the largest criminal fine for an individual corporation ever imposed in a US criminal prosecution of any kind. [124][125] "That was a blemish for us," John C. Lechleiter, CEO of Lilly, said.
"We don't ever want that to happen again. We put measures in place to assure that not only do we have the right intentions in integrity and compliance, but cialis 10mg tablets price we have systems in place to support that. "[231] In an internal email, Lechleiter had stated "we must seize the opportunity to expand our work with Zyprexa in this same child-adolescent population" for off-label use. In January 2020, lawyer James Gottstein published a book titled The Zyprexa Papers, summarizing the legal activities surrounding Zyprexa and their impact on the political landscape of psychiatry and antipsychiatry in the US. [233] The book details how he obtained the Zyprexa papers, including how Will Hall and a small group of "psychiatric survivors" spread the Zyprexa Papers on the Internet, and Gottstein's battles on behalf of Bill Bigley, the psychiatric patient whose ordeal made possible the exposure of the Zyprexa Papers.